PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer. PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer. PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer. [email protected]2023-12-04T17:17:51+00:00 Read More 0
